SCHEMBL3887906

SCHEMBL3887906

O=C(O)CCc1ccc(OCc2ccc3ccccc3c2)c(-c2ccc3[nH]ccc3c2)c1

nearest known ligand 0.53

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 9/20 0.53
ENPP2 Q13822 1/20 0.46
FFAR1 O14842 10/20 0.46
CYP1A2 P05177 1/20 0.44
AKR1B1 P15121 1/20 0.43
TP53 P04637 1/20 0.42
MDM2 Q00987 1/20 0.42
PTGER1 P34995 1/20 0.42
PTGER4 P35408 1/20 0.42
PTGER3 P43115 1/20 0.42
PTGER2 P43116 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3881410 0.92 FFAR4 (0.53) FFAR4ENPP2FFAR1CYP1A2
SCHEMBL3882284 0.92 FFAR1 (0.55) FFAR4ENPP2FFAR1TP53MDM2
SCHEMBL3884915 0.91 ENPP2 (0.53) FFAR4ENPP2FFAR1AKR1B1PTGER1
SCHEMBL3883797 0.90 CCNC (0.46) FFAR4ENPP2
SCHEMBL3883826 0.87 FFAR1 (0.59) FFAR4ENPP2FFAR1TP53MDM2
SCHEMBL3882044 0.87 FFAR4 (0.61) FFAR4ENPP2FFAR1
SCHEMBL3881198 0.87 TP53 (0.49) FFAR4ENPP2FFAR1TP53MDM2
SCHEMBL3884456 0.86 FFAR1 (0.60) FFAR4FFAR1AKR1B1PTGER1PTGER4
SCHEMBL3882508 0.86 MAOB (0.44) FFAR4ENPP2FFAR1TP53MDM2
SCHEMBL3882645 0.86 FFAR4 (0.55) FFAR4ENPP2FFAR1PTGER1PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 FFAR4 115/4885ENPP2 333/4885FFAR1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.